ALX-001
Alzheimer's Disease
Key Facts
About Allyx Therapeutics
Allyx Therapeutics is a private, Series A-stage biotech based in New Haven, CT, pioneering a synapse-protection approach for neurodegenerative diseases. Its lead asset, ALX-001, is a first-in-class, oral mGluR5 modulator that has completed Phase 1a/b studies, demonstrating safety, full brain receptor occupancy, and progression into patient trials for both Alzheimer's and Parkinson's disease. The company is backed by venture capital and significant non-dilutive NIH funding, positioning it to advance into Phase 2 clinical development.
View full company profileAbout Allyx Therapeutics
Allyx Therapeutics is a private, Series A-stage biotech based in New Haven, CT, pioneering a synapse-protection approach for neurodegenerative diseases. Its lead asset, ALX-001, is a first-in-class, oral mGluR5 modulator that has completed Phase 1a/b studies, demonstrating safety, full brain receptor occupancy, and progression into patient trials for both Alzheimer's and Parkinson's disease. The company is backed by venture capital and significant non-dilutive NIH funding, positioning it to advance into Phase 2 clinical development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |